en Clinical Medicine Clinical Medicine کارآزمایی بالینی Clinical Trials <span style="font-size:10pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white">Background & Objective:</span></span></span></b><b> </b>Febrile seizure (FS) is the most common childhood seizure disorder that occurs in 3-4% of children<span lang="EN" style="font-size:9.0pt"> .The aim of this study was to determine the effect of intermittent oral anticonvulsant Levetiracetam in prevention of the recurrence of febrile seizure (FS) in children.</span><b> </b><span style="font-size:9.0pt"><span style="color:black"></span></span></span></span><br> <span style="font-size:10pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="line-height:115%"><span style="color:white"><span style="letter-spacing:-.1pt">&nbsp;Materials & Methods:</span></span></span></span></span></b> <span lang="EN" style="font-size:9.0pt"><span style="line-height:115%">This a randomized clinical trial study was conducted on 108 children with FS referred to the pediatric department of Mohammad Kermanshahi Hospital in Kermanshah in 2020. Then, eligible patients were divided into intervention (Levetiracetam; n= 72) and control (Acetaminophen; n= 36) groups using balanced block randomization. The intervention group received a dose of 30-60 mg/kg Levetiracetam during the febrile illness</span></span> <span lang="EN" style="font-size:9.0pt"><span style="line-height:115%">for prophylaxis for 9 months. In contrast, in the control group, only acetaminophen was prescribed just to reduce fever. Finally, the number of FS recurrences were studied in two groups</span></span><span lang="EN" style="font-size:9.0pt"><span style="line-height:115%"><span calibri="" style="font-family:">.</span></span></span><span style="font-size:9.0pt"><span style="line-height:115%"> The data were analyzed using SPSS 26.</span></span><span lang="EN" style="font-size:9.0pt"><span style="line-height:115%"></span></span></span></span></span><br> <span style="font-size:10pt"><span new="" roman="" style="font-family:" times="">&nbsp;<b><span lang="EN-IN" style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white">Results: </span></span></span></b><b>&nbsp;</b><span lang="EN" style="font-size:9.0pt">The mean (&plusmn;S.D) age were 2.37 (&plusmn;1.01) vs. 2.30 (&plusmn;0.95) years in the intervention and control groups; respectively. The number (%) of boys in the two groups under study was 39 (54.1) and 19 (52.7), respectively. The mean time to first seizure recurrence after the intervention was significantly longer in the intervention group (5.70 &plusmn; 0.82 months) than in the control group </span><span style="font-size:9.0pt">(2.32 &plusmn; 0.75 months) (<i>P-Value<0.05</i>). Also, </span><span lang="EN" style="font-size:9.0pt">the mean number of recurrences of FS in the intervention group (</span><span style="font-size:9.0pt">2.25 &plusmn; 0.80</span><span lang="EN" style="font-size:9.0pt">) was significantly lower than the control group (</span><span style="font-size:9.0pt">4.13 &plusmn; 0.79</span><span lang="EN" style="font-size:9.0pt">) </span><span style="font-size:9.0pt">(<i>P-Value<0.05</i>). <span style="color:black"><span style="letter-spacing:-.1pt"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="line-height:115%"><span style="color:white">Conclusion: </span></span></span></span></b><span lang="EN" style="font-size:9.0pt"><span style="line-height:115%">The administration of oral anticonvulsant Levetiracetam may be effective in the reduction of the recurrences of FS, however, detailed studies in this field is recommended.</span></span></span></span></span> Levetiracetam, Recurrence, Febrile seizure, Children, Clinical trial study 168 173 http://journal.zums.ac.ir/browse.php?a_code=A-10-6883-1&slc_lang=en&sid=1 Javad Shabani shabani56@yahoo.com 5200319475328460089405 5200319475328460089405 No Kermanshah University of Medical Sciences, Kermanshah, Iran Mitra Hemmati semmatim744@yahoo.com 5200319475328460089406 5200319475328460089406 No Kermanshah University of Medical Sciences, Kermanshah, Iran Mostafa Sedighi sedighimostafa2000@gmail.com 5200319475328460089407 5200319475328460089407 Yes Kermanshah University of Medical Sciences, Kermanshah, Iran